| 2022 | A New Murine Liver Fibrosis Model Induced by Polyhexamethylene Guanidine-Phosphate | 임경민; 김민정 | Article |
| 2025 | Cannabigerol attenuates liver fibrosis via AMPK activation: Regulation of lipid metabolism, inflammation, and hepatic stellate cell activation | 권영주; 전경화; 박서정; 박은선 | Article |
| 2026 | Chrono-optimal treatments for human immunodeficiency virus/hepatitis C virus co-infection yield comparable survival outcomes with hepatitis C virus mono-infection | 정재윤 | Article |
| 2019 | Conditioned Medium from Tonsil-Derived Mesenchymal Stem Cells Relieves CCl4-Induced Liver Fibrosis in Mice | 유경하; 우소연; 김한수; 박주원; 김유희; 조경아 | Article |
| 2024 | Effect of direct-acting antivirals on disease burden of hepatitis C virus infection in South Korea in 2007–2021: a nationwide, multicentre, retrospective cohort study | 김휘영 | Article |
| 2023 | Endothelial TAZ inhibits capillarization of liver sinusoidal endothelium and damage-induced liver fibrosis<i> via</i> nitric oxide production | 황은숙 | Article |
| 2024 | Engineered lipid nanoparticles enable therapeutic gene silencing of GTSE1 for the treatment of liver fibrosis | 이혁진; 서원효; 신수민 | Article |
| 2023 | Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes | 이민종; 전호수 | Article |
| 2023 | MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study | 전호수 | Article |
| 2021 | MicroRNA-223 restricts liver fibrosis by inhibiting the TAZ-IHH-GLI2 and PDGF signaling pathways via the crosstalk of multiple liver cell types | 서원효 | Article |
| 2023 | Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future | 이한아 | Review |
